TAYSHA GENE T. DL -,00001

Taysha reported an EPS loss of $0.13 in Q2 versus a consensus of $0.12, prompting an after-hours sell-off of about 7.0%. The net loss widened to $46.6 million from $26.9 million a year earlier, driven by increased R&D and administrative expenses related to process qualification and patient recruitment for the REVEAL and ASPIRE studies. The company closed the quarter with $455.4 million in cash following a $230.0 million follow-on financing in June. Positively, TSHA-102 was well tolerated in 33 treated patients, but the market focus is now on cash burn ahead of the expected 2027 milestones. » More on de.investing.com

Taysha has signed a commercial manufacturing agreement with Catalent for the gene therapy TSHA-102 to treat Rett syndrome; Catalent is to act as the primary commercial manufacturer upon potential FDA approval. Catalent will handle GMP-compliant production and commercial supply at its licensed facility in Harmans, Maryland; the companies have collaborated since 2020. Process qualification activities for TSHA-102 are currently underway as part of the BLA. » More on de.investing.com

Taysha Gene Therapies’ stock reached a new all-time high of 5.49 USD but remains below its 52-week high of 7.30 USD and fell nearly 8% on the week. Over the past year the share price rose by almost 100%, while InvestingPro classifies the stock as overvalued. For Q1 2026 Taysha reported a net loss of 0.12 USD per share (expectation: -0.10 USD) and no revenues (expectation: 850,000 USD), yet showed slight strength in premarket trading. Investors are now watching the company’s strategic responses in light of missing revenue and missed forecasts. » More on de.investing.com